Selective DNA-PK inhibitor, M3814, boosts p53 apoptotic response to DNA double strand breaks and effectively kills acute leukemia cells: Implications for AML therapy

被引：2
|
作者：
Haines, Eric [1 ]
Zimmermann, Astrid [2 ]
Zenke, Frank [2 ]
Blaukat, Andree [2 ]
Vassilev, Lyubomir T. [1 ]
机构：
[1] EMD Serono Res & Dev Inst Inc, Billerica, MA USA
[2] Merck KGaA, Merck Biopharma, Darmstadt, Germany
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-4830
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4830
引用
收藏
页数：1
相关论文
共 9 条
  • [1] M3814: A novel investigational DNA-PK inhibitor to target DNA double strand break repair
    Zenke, F. T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814
    Sun, Qing
    Guo, Yige
    Liu, Xiaohong
    Czauderna, Frank
    Carr, Michael I.
    Zenke, Frank T.
    Blaukat, Andree
    Vassilev, Lyubomir T.
    MOLECULAR CANCER RESEARCH, 2019, 17 (12) : 2457 - 2468
  • [3] DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia
    Carr, Michael, I
    Zimmermann, Astrid
    Chiu, Li-Ya
    Zenke, Frank T.
    Blaukat, Andree
    Vassilev, Lyubomir T.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [4] DNA-PK inhibitor, M3814, as a new combination partner of Mylotarg in the treatment of acute myeloid leukemia
    Zimmermann, Astrid
    Carr, Michael
    Zenke, Frank T.
    Blaukat, Andree
    Vassilev, Lyubomir T.
    CANCER RESEARCH, 2019, 79 (13)
  • [5] A novel selective DNA-PK inhibitor, M3814, as a potential combination partner of Etoposide and Cisplatin in the therapy of lung cancer
    Sirrenberg, Christian
    Zimmermann, Astrid
    Grombacher, Thomas
    Vassilev, Lyubomir T.
    Damstrup, Lars
    Zenke, Frank T.
    Blaukat, Andree
    CANCER RESEARCH, 2017, 77
  • [6] TP53 status determines the fate of cancer cells exposed to ionizing radiation and DNA-PK inhibitor, M3814
    Sun, Qing
    Guo, Yige
    Liu, Xiaohong
    Czauderna, Frank
    Zenke, Frank
    Blaukat, Andree
    Vassilev, Lyubomir T.
    CANCER RESEARCH, 2018, 78 (13)
  • [7] DNA-PK inhibitor, M3814, is a potent inducer of inflammatory micronucleation in irradiated p53-deficient cancer cells: Implications for combination radio-immunotherapy
    Carr, Michael
    Zimmermann, Astrid
    Guo, Yige
    Liu, Xiaohong
    Steiner, Patrick
    Hahn, Susanne
    Zenke, Frank
    Blaukat, Andree
    Vassilev, Lyubomir T.
    CANCER RESEARCH, 2019, 79 (13)
  • [8] DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia
    Eric Haines
    Yuki Nishida
    Michael I. Carr
    Rafael Heinz Montoya
    Lauren B. Ostermann
    Weiguo Zhang
    Frank T. Zenke
    Andree Blaukat
    Michael Andreeff
    Lyubomir T. Vassilev
    Scientific Reports, 11
  • [9] DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia
    Haines, Eric
    Nishida, Yuki
    Carr, Michael, I
    Montoya, Rafael Heinz
    Ostermann, Lauren B.
    Zhang, Weiguo
    Zenke, Frank T.
    Blaukat, Andree
    Andreeff, Michael
    Vassilev, Lyubomir T.
    SCIENTIFIC REPORTS, 2021, 11 (01)
1